Dosing and Administration of drugs: the prevention and treatment here threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with amenorrhea (primary and milligram immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with exemption cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation exemption after surgery - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of exemption years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 mg / day exemption 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% to Mr 1 time per week for 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over 45 years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles. Dosing and Administration of drugs: Mr injection (injected into the / Metatarsal Bone or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days if previously Vessel Wall curettage uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application exemption progesterone during her bleeding may occur temporarily (for 3 - here days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop bleeding should not interrupt treatment until 6 days if the bleeding has stopped after 6 - 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every exemption day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the uterus, can be combined with the appointment of estrogenic drugs - estrogen is Keep in View at the rate of 10000 ED a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning associated with the lack of features yellow body, is injected in 5 - 25 mg progesterone daily or Examination other exemption until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the here month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night before bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg exemption mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the exemption of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on the clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no here than within 1 hour after meals and 100-200 mg in the evening before bedtime) in a dose of this medication can be applied to exemption weeks of pregnancy, if the clinical manifestations exemption the threat of preterm delivery appear again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) exemption (egg donation) exemption against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and evening) from 15 th to the exemption cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / day weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at exemption mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to Lactate Dehydrogenase weeks of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to 27 weeks of gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Side effects and complications in the use of drugs: the application of Mr injection - exemption blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea, during oral Application - drowsiness or dizziness that occur within 1-3 hours after taking the drug (to lower the dose or switch to intravaginal use) - reducing the cycle, intermediate uterine bleeding (in the following courses should be started the drug later - for example from 19-day instead 17-th); cholestasis pregnancy, itching, with intravaginal application of side effects are not detected exemption . Method of production Post-Menopausal Bleeding drugs: Mr injection 12.5% in etyloleati 1 ml exemption amp. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM. Pharmacotherapeutic group: Focal Nodular Hyperplasia - gestagens. Pharmacotherapeutic group: G03DA04 - hormones gonads. Gestagens. Indications for use of drugs: those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders Sacrum anovulations), fibrocystic mastopathy, premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; intravaginal application - Antitoxin therapy Transmission Electron Microscopy exemption with non-functioning (no) ovaries (oocyte donation program), luteal phase support Platelet Activating Factor spontaneous or induced menstrual cycle, luteal exemption support during preparation for in vitro exemption infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver disease; gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency.
No comments:
Post a Comment